Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

PTGX

PR Newswire

MILPITAS, Calif., Sept. 11, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., the Company's President and Chief Executive Officer, will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26 from 9:45 - 10:15 am ET.  The conference is being held at the InterContinental New York Barclay Hotel in New York, NY.

Protagonist Therapeutics, Inc. (PRNewsFoto/Protagonist Therapeutics, Inc.)

A live and archived audio webcast of the presentation can be accessed by visiting the Investors page of Protagonist Therapeutics corporate website at http://investors.protagonist-inc.com.

About Protagonist Therapeutics
Protagonist Therapeutics is a clinical development-stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. Lead peptide candidates, PTG-100 and PTG-200, are based on this approach. PTG-100 is currently in Phase 2b clinical trials for moderate-to-severe ulcerative colitis, and the company plans to initiate clinical trials of PTG-200 in 2017 as a potential treatment for Crohn's disease.  The company recently entered into a worldwide collaboration with Janssen Biotech to co-develop and commercialize PTG-200.  Protagonist is also developing an injectable hepcidin mimetic, PTG-300, for the treatment of rare diseases such as beta-thalassemia, currently in a Phase 1 clinical trial.

Protagonist is headquartered in Newark, California with pre-clinical and clinical staff in California, and discovery operations both in California and Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-300517245.html

SOURCE Protagonist Therapeutics, Inc.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today